monuvir 200mg - 200 MG

Cream

Pack Size : 1 Tube x 1 Packet

Generics : Molnupiravir

Manufacturer : Eskayef Pharmaceuticals Ltd.

Best Price * TK 50.00

* Delivery will be done in Dhaka city only.

Alternative Product

Capsule emorivir 200mg - 200 mg Beximco Pharmaceuticals Ltd.

Tk 45.00

More Information About - monuvir 200mg - 200 MG

Description

Generic Name

Molnupiravir

Precaution

? Embryo-Fetal Toxicity: Molnupiravir is not recommended for use during pregnancy. ? Bone and Cartilage Toxicity: Molnupiravir is not authorized for use in patients less than 18 years of age because it may affect bone and cartilage growth.

Indication

Indicated for treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults with a positive SARS-COV-2 diagnostic test and who have at least one risk factor for developing severe illness. Such risk factors include obesity, older age (>60 years), diabetes mellitus, or heart disease.

Contra Indication

Hypersensitivity to the active substance or to any of the excipients

Dose

N/A

Side Effect

The most common adverse reactions (?1% of subjects) reported during treatment and during 14 days after the last dose were diarrhoea (3%), nausea (2%), dizziness (1%) and headache (1%) all of which were Grade 1 (mild) or Grade 2 (moderate).

Pregnancy Category

Name : Not Classified

Description

FDA has not yet classified the drug into a specified pregnancy category.

Mode of Action

Molnupiravir is a prodrug that is metabolised to the ribonucleoside analogue N-hydroxycytidine (NHC) which distributes into cells where it is phosphorylated to form the pharmacologically active ribonucleoside triphosphate (NHC-TP). NHC-TP acts by a mechanism known as viral error catastrophe. NHC-TP incorporation into viral RNA by the viral RNA polymerase, results in an accumulation of errors in the viral genome leading to inhibition of replication.

Interaction

N/A

Pregnancy Category Note

Pregnancy: The use of molnupiravir is not recommended during pregnancy. Advise individuals of childbearing potential to use effective contraception correctly and consistently, as applicable, for the duration of treatment and for 4 days after the last dose of molnupiravir. Lactation: Breastfeeding is not recommended during treatment and for 4 days after the last dose of molnupiravir. A lactating individual may consider interrupting breastfeeding and may consider pumping and discarding breast milk during treatment and for 4 days after the last dose of molnupiravir.

Adult Dose

Adults The recommended dose is 800 mg (four 200 mg capsules) taken orally every 12 hours for 5 days. Hepatic Impairment No dose adjustment is required for patients with hepatic impairment

Child Dose

Molnupiravir is not authorized for use in patients who are less than 18 years of age.

Renal Dose

Renal Impairment No dose adjustment is required for patients with renal impairment

Administration

Can be taken with or without food.

Disclaimer

The information provided herein are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please note that this information should not be treated as a replacement for physical medical consultation or advice. Great effort has been placed to provide accurate and comprehensive data. However, Medicart along with its authors and editors make no representations or warranties and specifically disclaim all liability for any medical information provided on the site. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company.